Combined Inhibition of MNK Signaling and BET Proteins Reveals TGM2 as a Novel Vulnerability in Melanoma

Affiliations

• ¹ Lady Davis Institute, Jewish General Hospital, Montréal, Canada; Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, Canada.
• ² Lady Davis Institute, Jewish General Hospital, Montréal, Canada; Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, Canada; School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
• ³ Lady Davis Institute, Jewish General Hospital, Montréal, Canada.
• ⁴ Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Canada.
• ⁵ Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Canada; Manitoba Centre for Proteomics and Systems Biology, University of Manitoba, Winnipeg, Canada.
• ⁶ Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Canada; Department of Oncology, McGill University, Montréal, Canada.
• ⁷ Lady Davis Institute, Jewish General Hospital, Montréal, Canada; Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, Canada; Department of Oncology, McGill University, Montréal, Canada.
• ⁸ Lady Davis Institute, Jewish General Hospital, Montréal, Canada; Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, Canada; Department of Oncology, McGill University, Montréal, Canada. Electronic address: soniavictoria.delrincon@mcgill.ca.
• ⁹ Lady Davis Institute, Jewish General Hospital, Montréal, Canada; Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, Canada; Department of Oncology, McGill University, Montréal, Canada. Electronic address: michael.witcher@mcgill.ca.